Press Releases
Cell Signaling Technology Announces Pilot Study to Evaluate CST’s PhosphoScan® Platform for Kinase Inhibitor Phosphoproteomic Profiling
Beverly, MA, August 1, 2005 – Cell Signaling Technology, Inc. (CST) announced today an agreement with Novartis under which a pilot study was performed with CST’s PhosphoScan® technology to identify phosphorylation sites and prospective biomarkers of protein kinase targets. CST’s PhosphoScan® phospho-proteomics technology enables the determination of cellular kinase phospho-profiles (Phospho-Signatures®) and is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy. The PhosphoScan® technology was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The phospho-profiles discovered with PhosphoScan® may enable biomarker assays for target validation and kinase inhibitor clinical development.
“Our PhosphoScan® pilot with Novartis was a great opportunity to demonstrate the utility and value of cellular phospho-profiles and modulation of these by kinase inhibitors,” said Christopher Bunker, CST’s Director of Pharma Services. “We are able to use PhosphoScan® to deliver focused, in-depth Phospho-Signatures® of disease cells and tissues and provide the basis for kinase biomarkers. CST superiority in antibody and immunoassay development is fully integrated with PhosphoScan®, and this can enable CST to translate PhosphoScan® discoveries into validated biomarker assays.”
About Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST’s phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. CST has leveraged its antibody core capabilities to develop PhosphoScan®, a superior phospho-proteomics platform that can enable more efficient and informative kinase drug discovery and clinical development. CST is commercializing the PhosphoScan® technology through research alliances and licensing opportunities. Information on CST can be obtained at the Company’s website at www.cellsignal.com
